Control serum levels of IL-6 measured by ELISA in 30 healthy blood donors or volunteers were 18±34 pglml (mean ± sm. Pretransplant serum levels of in 169 adult candidates for liver transplantation were significantly higher than control in those with fulminant hepatitis (203:232 pglml) , alcoholic cirrhosis (116:257 pglml), and hepatocellular carcinoma (82: 105 pglmD. With these data as background, plasma or serum levels of IL-6 were monitored in 24 adult patients after first OLT and correlated with the clinical courses and the histopathological diagnosis of rejection. Serum or plasma levels of IL-6 decreased after transplantation regardless of pretransplant value. Four patients with infection subsequently developed continuously high IL-6 values. In the 20 of 24 patients who did not have infection, significantly higher levels of IL-6 were consistently found 0-4 days before histopathological diagnosis of rejection (131±78 pglml) compared with significantly lower values in patients without rejection episodes (40:21 pglmD. The elevations of IL-6 were spike shaped, did not correlate well with the histopathological grades of rejection. and were highly responsive to augmented immunosuppression. These 20 cases were classified as: group I, no spikes of IL-6 after liver transplantation; group 2, single spike of IL-6 after liver transplantation; and group 3, multiple spikes of IL-6 after liver transplantation. The combined early and late graft loss of each group was 0% (group 1),25% (group 2', and 67t:"c (group 3). We conclude that daily monitored serum or plasma IL-6 levels can be a good premonitor of liver allograft rejection and also a useful predictor of long-term graft outcome.
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The diagnosis of liver allograft rejection is based largely on liver function tests. Although they can assess the graft damage associated with rejection, histopathological findings have been the gold standard. Markers of immune activation and mediators of inflammation, such as IL-2, soluble IL-2R I sIL-2R l. * and TNF -a could provide noninvasive methods of diagnosis of rejection, IL·6 is an immunoregulator of cell growth and differentiation that is produced mainly by human monocytes/macrophages, fibroblasts, endothelial cells. and activated T cells ( 1 !. IL-6 is one of the principal mediators of intlammation (2) and an inducer of the hepatic svnthesis of the maJonty of acute phase proteins (3, .J J. Because the liver is a major target organ for IL-6 (5)' and because allograft rejection is fundamentally an inflammatory response. we prospectlvelv studIed the relationship of serum or plasma IL-6 after liver transplantation and liver allograft rejection.
MATERIALS AND METHODS
Healthy volunteers, IL-6 was measured in 30 randomly selected blood donors and healthy laboratory personnel.
Liver transplant candidates. Preoperative IL-6 was measured in 169 consecutive infection-free candidates for first OLT or abdominal organ cluster transplantation between March 1988 and November 1990 at the Presbyterian-University Hospital of Pittsburgh, Univer· sity of Pittsburgh, Pittsburgh, PA. The age, sex. and original disease distribution are listed in Table 1 .
Liver transplant recipients. Twenty-four adult patients (15 males and 9 females, mean age 49.3 years, range 28-64 years) who actually underwent first OLT were selected randomly for pre· and postoperative IL-6 studies between November 1989 and March 1990. The indications for OLT were chronic active hepatitis in 3, cirrhosis in 19, and malignancy in 2 ( Table 2 ). The mean follow-up for IL·6 measurement was 26 days (range 13-48 days),
Immunosuppression. Baseline immunosuppression was with FK506 (n=22' or CsA(n=2l. to which variable doses ofmethylprednisolone were added; OKT3 was given when indicated. One CsAtreated patient was SWitched to FK506 because of CsA-resistant rejection.
Diagnosis and treatment of rejection. Episodes of rejection sus· pected on clinical grounds were confirmed by histopathological findings of biopsy specimens. Grading of acute cellular rejection was by one of us (A.J.D.,.lnitial treatment of rejection was with intravenous methylprednisolone (steroid bolus). Patients failing to respond were given high·dose steroid recycle over 5 days, or OKT3 was instituted.
Samples. Blood samples were separated to serum (all candidates, 169 samples: 8 OLT reCipients. 123 samples 1 or plasma t 16 OLT recipients. 284 samples I. The blood samples were maintained at 4°C during preparation. and the serum or plasma stored at -20°C. The postoperative samples were collected daily. except on weekends. In patients suspected of reJl'ction. samples were aiways taken on the day of biopsy, and the :2 succeeding days. In most of these cases, samples were available for the preceding 4 days.
IL·6 Assa.v. ELISA was performed by two-step sandwich enzyme Immunoassay method usmg a commerCially available ELISA kit IQuantikine human IL-6 immunoassay, Research and Diagnostic SYstems. Inc .. Minneapolis. MN). according to the manufacturer's i~structions. Briefly, 50 III of assay butTer t buffered protem base) were added to 96-well microplates coated with mouse anti-human I L·6 mAb t first antibody I. Then. 200 III of test samples were added to mIcroplates. After :.I-hr incubation at room temperature. the wells were washed, 200 Ill. of horseradish peroxidase-conjugated goat anti· human lL-6 polyclonal antibodv were added. and incubation was earned out at room temperature tor :.I hr. The wells were washed as above and incubated at room temperature jt)r 20 mm With chromo· ~en. which was a mixture of HeO, and tetramethvlbenzidine. After a last incubation. 50 III of 2~ H.$O, were added to stop the reaction :lnd optical density at ~50 nm was measured using a microtlter n'ader tTitertek Multiskan. Flow Laboratones. Inc .. McClean. VAl. The standard curve for IL-6 ran~ng from a1.3 pgJml to 2000 pgtml was drawn bv logllog scale. IL-6 values of the samples were calcu- ; Hepatocellular carcinoma; hepatocellular carcinoma with PNC due to viral hepatitis (n = 1), hepatocellular carcinoma with alcoholic cirrhosis (n peak levels of IL-6 after OLT were determined as mean ::: SD. A P-value of less than 0.01 was considered significant.
RESULTS
Health.v volunteers. The nonnal mean value ofIL-6 from 30 healthy volunteers was 18~34 pglml (range 0-158 pglmll. 1Wenty-one (70%) had nondetectable« 10 pglmO levels. We defined the normal IL-6 cutoff level as 86 pglml, which was the mean::: 2S0 value of the 30 healthy volunteers. Two (7'1:) of the 30 had lL-6 levels greater than 86 pglml.
Correlation between serum and plasma leL'els of IL-6. A high degree of correlation was found between serum and plasma levels of lL-6 from 10 same blood samples (r=0.991).
Serum levels 01" IL-6 in 169 liver transplant candidates.
Elevated serum levels greater than the cutoff value of 86 pglml were observed in the patients with fulminant hepatitis 150'7r: mean :203:::232 pglmil alcoholic cirrhosis (24%: mean 116 ~257 pg/ml). and hepatocellular carcinoma 133%: mean ,'i~::: 105 pglmll. Candidates With other diseases had IL-6 within the :.2 SO range I Table 1 ).
IL-6 mOnitoring ol24 liver transplant reciplents. The 24
patients studied postoperatively had a total of 28 liver transplants: J reqUired retransplantatlOn because of primary nonfunction In =:2) or rejection (n = 11 and 1 required a third transplantatIOn because of persistent rejection. The shortest hospital course was 13 days and the longest course was 8 months. The latter patient died of sepsis and multiple svsterns organ failure. A total of 407 (123 serum and 284 plasma, ~amples were analyzed for IL-6 concentration over the average monitoring period of 26 days (range 13-48 days). In the patients without infection and with stable well-functioning grafts, serum or plasma lL-6 levels remained within normal range no matter what the pretransplant values (Fig. 1) POI'"".'O"" cia,. increased IL-6 levels during these episodes to as high as or higher than 1000 pgJml. With acute cellular rejection in the 20 uninfected patients. IL-6 was increased from 0 to 4 days before the histopathological diagnosis of rejection. These elevations occurred in sPlkes. and always fell rapidly Wlthin 48 hr after the institution of antirejection therapy whether this was successful or not. However. when rejection was not controlled or recurred. IL-6levels increased again. A total of29 biopsles were done in these 20 reCIpients during the IL-6 momtoring penod. Twenty-one of the biopsles had unequivocal eVidence of acute cellular rejection. whereas 8 had equivocal or no evidence of reJectIOn. With a histopathological diagnosis of rejection. the mean peak values of IL-6 levels were 131:!: 78. and without this diagnosis the values were 40:::21 (P<O.Oll. A mean peak value of serum IL-6 levels was weater than ti6 pgJml in 76th-of the rejection group and Ot} in the nonreJection group ( P<O.Oll.
O+---~------------~------~~~----+O
In the uninfected patients with acute cellular rejection. there was not a clear correlation between IL-6 peak values and histopathological grades of rejection. nor was there a correlation between IL-6 levels and white blood cell count. total bilirubin. serum glutamic oxaloacetic transaminase. serum glutamic pyruvic transaminase. alkaline phosphatase. and "y-GTP levels. Rather. the correlation appeared to be between the outcome and number ofIL-6 spikes (Table 3) , However. when these 20 patients were classified according to the numbers of IL-6 spikes as group 1 (no spike). group 2 (single spike). and (3) woup 3 (multiple spikes). those of group 3 ,.;utfered severer histopathological reJectIOn and a higher mortality.
IL-6 levels from 4 representative patients (3 uninfected and 1 infected) are plotted in Figure : 2. Fih>'Ure 2A shows a normal IL-6 protile of a patlent who had an uneventful postoperative course. The patient in Figure : 2B had a moderate rejection with an IL-6 spIke on the sixth postoperative day (POOl. a biopsy shOWIng rejection on POD 7. and successful treatment with sterOIds on POD 8.
The course in Figure : lC is from a patient with early ischemic injury and later severe acute cellular rejection. Postop-
eratively, IL-6 levels were low on POD 5, at which time the biopsy showed ischemic damage. The markedly increased early postoperative bilirubin levels gradually fell until the diagnosis of mild acute cellular rejection was made on POD 21. Two days before this diagnosis. IL-6 levels increased slightly. Eight days later. severe acute cellular rejection was diagnosed by biopsy, at which time there was an IL-6 spike that resolved with OKT3 treatment. Figure 2D shows the IL-6 values of a patient with necrotizing fasciitis and abdominal abscesses from the second postoperative week. IL-6 levels rose steadily to astronomical levels.
DISCUSSION
Recently, measurements of plasma. serum, urine, or bile cytokine levels have been reported as indicators of the early diagnosis of rejection. Products of activated T lymphocytes. such as IL-2 or soluble components of its receptor (sIL-2Rl. have been particularly well studied. Perkins et a1. (6) and Adams et al. (7) reported the efficacy of sIL-2R in serum and bile as an indicator of liver allograft rejection. but these measures have not been widely applied. The monocyte/macrophage-derived cytokines, TNF-a, and IL-6 are released in relatively large amounts early in the immune activation process and can be detected readily in the circulation by a sensitive ELISA assay. Imagawa et al. (8) described elevated serum TNF-a values as predictive of human liver allograft rejection and, in rats, Tono et al. (9) observed that bile IL-6 levels correlated with the severity of rejection. Van Oers et al. ( 10) and Yoshimura et a1. ( 11 ) reported the efficacy of IL-6 for diagnosing renal allograft rejection.
In our study, it was observed that the pretransplant IL-6 value depended upon the nature of the original liver disease. Preoperative elevations were common with fulminant hepatic failure. alcoholic cirrhosis, and neoplastic disease. In fulminant hepatIC failure. or with end-stage chronic failure. sepsis and endotoxemia and/or impairment of liver reticuloendothelial system function are common (121. This reticuloendothelial system function impairment allows a variety of gut-derived antigens to be released into the general circulation. presumably \V1th IL-6 production. Muto et al. (] 3) reported that TNF-a production was increased and correlated closely with activity of IL-l. IL-6 is also a monokine produced by monocytesimacrophages in response to infection and endotoxin. Alcohol increases the permeability of gastrointestinal mucosa. and could result in increased absorption of macromolecules. such as dietary or bacterial proteins, into the general circulation. Alcohol also impairs Kupffer cell phagocytic function. theoretically predisposing to excessive production of IL-6 with alcoholic cirrhosis. Deviere et al. (J4, 15) have reported increased serum levels of IL-6 and in vitro spontaneous or induced excessive production of IL-6 by PBMe of alcoholic cirrhosis patients.
In patients with hepatocellular carcinoma. elevated serum IL-6 levels also have been reported, which is not surprising because IL-6 is a common participant in the host-tumor interaction (J6). Increased erythrocyte sedimentation rate, increased serum levels of acute phase proteins, decrease in serum albumin, and fever are common systemic features in tumor-bearing hosts. These features are strongly associated with the function of IL-6. Tabibzadeh No matter what the pretransplant value. our studies suggest that IL-6 levels in the absence of infection are initially normalized with successful o LT. These observations are potentially at variance with those of Fugger et al. (20) , who reported that intraoperative endotoxin. TNF-a, and IL-6 were closely (and presumably causally) related to postoperative rejection and infection; such an association of preoperative endotoxin and postoperative morbidity also has been reported in our earlier cases by Yokoyama et a1. (12) and Miyata et al. (21) . The normalization in our patients was interrupted by rejection.
Rejecting liver allografts are characterized by a cellular infiltration consisting mainly of monocyteslmacrophages and T lymphocytes, all of which may secrete IL-6. In addition. liver Kupffer cells and vascular endothelial cells also secrete IL-6. Therefore. infiltrating host immune cells or cells of the allograft could have a role in producing IL-6. In addition. the liver is the major target organ of IL-6 (.5). In a counterregulatory process. IL-6 stimulates pituitarY cells to release adrenocorticotrophic hormone and subsequently result in the synthesis of corticosteroids (221. The systemic glucocorticosteroids inhibit production of IL-6. The data herein reported have suggested a possibility of IL-6 regulation by steroid 1041 treatment inasmuch as lL-6 levels fell within 48 hr of bolus steroid therapy, whether or not rejection was brought under control. The direct influence of other immunosuppressive drugs on IL-6 can only be speculated upon. CsA and FK506 are thought not to inhibit IL-6 production in vitro (23) . Anti-CD3 murine mAb (OKT3) actually raises IL-6levels in transplant recipients (24, 25) . However, in our study, even in the patient treated with GKT3, we could not observe an increase of IL-6. IL-6 spikes always appeared at the time of first rejection episode, or with recurrence of rejection. These observations suggest that the rejection (or alternatively infection), rather than the drugs used for treatment, was the dominant factor in the determination of IL-6 levels.
In clinical application, the IL-6 rises due to rejection, whereas increases caused by infection appear to be distinguishable. With bacterial infection, serum IL-6 levels were unrelentingly elevated, usually to extraordinary heights (> 1000 pglmll. This pattern contrasted with the spikes of IL-6 seen with rejection that were quickly responsive to intensification of immunosuppression. The need for serial testing can be met with current technology. The IL-6 ELISA assay takes less than 5 hr.
